Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test

Executive Summary

Funding will accelerate an FDA registrational study of the company's first liquid biopsy product, as competition increases in early cancer detection.     

You may also be interested in...



Guardant Health Expects FDA Approval Of Liquid Biopsy Test Will Strengthen Coverage, Adoption

CEO sees Guardant360 CDx approval as "watershed moment" for liquid biopsy and plans more biopharma partnerships.

Grail Raises $390M In Series D Financing To Advance Blood Cancer Test

Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.

Partnerships Are Key To Foundation Medicine's Success

Since receiving approval for the first broad-panel diagnostic test as a combination product to detect cancer, Foundation Medicine has ramped up its partnerships with pharmaceutical companies and other stakeholders. The company expects to receive a similar approval for a broad-panel liquid biopsy genomic test in the first half of 2020.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel